172 results about "Spiroplasma" patented technology

Disclosed is a vaccine against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding Borrelia OspA or OspB, and a DNA encoding a terminator. Disclosed too is an immunogenic composition against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid comprising a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding a Borrelia OspC, and a DNA encoding a terminator. And, methods for making and using such vaccines and the immunogenic composition are also disclosed.

The present invention discloses hybridization assay probes, amplification primers, nucleic acid compositions and methods useful for detecting Borrelia nucleic acids. Hybridization assay probes and amplification primers that selectively detect Lyme disease-associated Borrelia and distinguish those Borrelia from Borrelia hermsii are disclosed. Other hybridization probes selectively detect Borrelia hermsii and not Lyme disease-associated Borrelia are also described.

Provided is a method of detecting transmissible spongiform encephalopathies. The method comprises: selecting a sample from a subject to determine whether the subject has a transmissible spongiform encephalopathy; and detecting spiroplasma-specific 16S rDNA indicative of transmissible spongiform encephalopathies in the sample. The spiroplasma-specific 16S rDNA is preferably detected by contacting the sample with a pair of oligonucleotide primers under polymerase chain reaction conditions and detecting the resulting polymerase chain reaction product, wherein each of the pair of the oligonucleotide primers is complementary to spiroplasma-specific 16S rDNA indicative of transmissible spongiform encephalopathies. Further provided is an oligonucleotide having a nucleotide sequence complementary to spiroplasma-specific 16S rDNA indicative of transmissible spongiform encephalopathies; as well as an oligonucleotide having a nucleotide sequence specific to spiroplasma-specific 16S rDNA indicative of transmissible spongiform encephalopathies.

The present invention relates to vaccines for control of Borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more Borrelia burgdorferi antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.

The invention aims to provide a reagent for assaying an antiphospholipid antibody which is excellent in long-term storage stability and capable of diagnosing syphilis infection or the like and a reagent for assaying an anti-Treponema pallidum antibody which is capable of diagnosing syphilis infection with high accuracy by preventing the occurrence of serum interference. The invention is directed to the reagent for assaying an antiphospholipid antibody to be used for diagnosing syphilis infection comprising an insoluble carrier carrying an antiphospholipid antigen and a copolymer with a segment derived from 2-methacryloyloxyethyl phosphorylcholine and a segment derived from a hydrophilic monomer.

A tablet for insertion into a vagina including 0.01 to 500 mg of a vaginal medication, such as a microbicide, such as cellulose acetate 1,2-benzenedicarboxylate (CAP); 100 to 500 mg of mannitol powder; 50 to 300 mg of inert microcrystalline cellulose; 10 to 80 mg of hydroxypropyl methylcellulose; 50 to 250 mg of glycerol and optionally 2 to 4 mg of at least one preservative which protects against microbicidal contamination and discourages the growth of yeast in the vagina. The tablet which includes CAP as the vaginal medication is vaginally administered before coitus in methods for preventing the sexual transmission of HIV-1, HIV-2, herpesvirus, or an infection caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Haemophilus ducreyi or Treponema pallidum. The tablet which includes CAP as the vaginal medication is vaginally administered to prevent or treat bacterial vaginosis.

The invention belongs to the technical field of immunoassay and diagnosis and relates to a method for magnetic antibody immunoassay chemiluminescence detection of treponema pallidum antibodies. The method comprises the following steps of: using GoldMag particles as carriers, coating one or more antigens of specific recombinant proteins of treponema pallidum antibodies, TP15, TP17, TP47 and TP44.5, then adding a sample to be detected and enzyme labeled antigens, and finally adding luminescence substrates for luminescence detection. The GoldMag particle surface has a larger coupling capacity to the antigen and has characteristics of high specificity and no pollution of the enzyme linked immunoassay as well as high sensitivity of chemiluminescence, and therefore, the method has the advantages of high detection sensitivity, good specificity, wide linear range, no radioactive pollution and the like.

The invention relates to a treponema pallidum (TP) antibody test kit based on the flow microspheric carrier technology and a preparation method and detection method thereof, belonging to the technical field of immunoassay medical diagnosis. The preparation method comprises the following steps: using TP recombinant antigen to coat heavy polymer microsphere, using bovine serum albumin to seal empty binding site, preparing specific TP probe-heavy polymer microsphere; performing coculture with a sample to be tested to capture TP antibody, washing and centrifuging to remove the unbound TP antibody, then adding fluorescently-labeled anti-human IgG or IgM antibody; and using a flow cytometry to detect the fluorescence intensity of the microsphere, and performing qualitative or quantitative analysis to the tested antibody. The method has the advantages of high sensitivity and specificity and good stability and can be used to perform microanalysis or multivalent analysis to the sample.

The invention discloses a herbal disinfectant for space spray disinfection. The herbal disinfectant is composed of fourteen pharmaceuticals including rhizoma atractylodis, rhubarb, coptidis rhizoma, herba artemisiae scopariae, radix angelicae dahuricae, cyrtomium rhizome, sweet wormwood herb, betel nuts, cloves, costustoot, borneol, mint, chrysanthemum, and agastache. The medicinal materials selected for the herbal disinfectant for space spray disinfection of the present invention have the functions of clearing heat and removing toxicity, removing miasmic toxin and dispelling filth, restoring consciousness and opening the orifices, supporting body healthy qi, and fending off evil. The volatile oils, alkaloids and other active ingredients contained in the medicinal materials have different levels of direct inhibition or killing function for a variety of bacteria, viruses, fungi, and spirochetes, mycoplasma, etc. The present invention utilizes a scientific method to extract total extract from the medicinal materials for preparing the space spray medicament, and has a good disinfection effect.

The invention relates to a trivalent gene recombination vaccine for preventing leptospirosis and a preparation method thereof and aims to effectively prevent infection of leptospira interrogans of different sero-groups with low manufacturing cost. The technical scheme is that: the trivalent gene recombination vaccine for preventing the infection of leptospira interrogans of different sero-groups consists of a lipL32/1 gene, a lipL21 gene and an ompL1/2 gene cloned from a leptospira icterohemorrhagiae genome; a fusion gene lipL32/1-lipL21-ompL1/2 prepared by a technique for gene engineering has a nucleotide sequence and an amino acid sequence shown in a sequence 5; and the lipL32/1 gene is connected with the lipL21 gene, and the lipL21 gene is connected with the ompL1/2 gene through two same flexible peptides shown in a sequence 4.

The invention discloses an isothermal chain multiple displacement detection card of pathogen nucleic acid. The isothermal chain multiple displacement detection card of the pathogen nucleic acid utilizes the detection card which is prepared through a nucleic acid isothermal chain displacement method and a colloidal gold detection technology to carry out multiple detection on HBV-DNA, HCV-RNA, HIV-RNA, and TP-DNA. The isothermal chain multiple displacement detection card of the pathogen nucleic acid has the characteristics of simple and rapid operation, high sensitivity, and no need of professional equipment. The pathogen nucleic acid to be detected is not amplified in the detection process, so the detection card has the advantages of preventing amplified matter cross contamination in laboratories and preventing false positivity, can be widely used in high sensitivity pathogen nucleic acid detection in the fields of clinical detection, inspection and quarantine, infectious disease control, biological technology and the like, and has a wide application prospect.

The invention provides a loop-mediated isothermal amplification method for detecting lyme disease spirochete. DNA (deoxyribonucleic acid) of a sample to be detected is subjected to constant temperature amplification reaction by adopting a FIP (forward inner primer) and a BIP (backward inner primer) and F3 and B3 (shown in Seq ID No.1-4). According to the loop-mediated isothermal amplification method, a LAMP (loop-mediated isothermal amplification) primer constant-temperature amplification technique is used for fast detecting the lyme disease spirochete, and the lyme disease spirochete can be accurately detected from suspected patient serum. The specificity and sensitivity of the method are higher than those of the common PCR (polymerase chain reaction). Different virulence genes of lyme disease spirochetes can be detected, and the method has significance in the aspects of early diagnosis and early treatment of the lyme disease and the like. Investment on an expensive apparatus can be avoided and the method is convenient for grass-root popularization and use.

The present invention provides a lyme disease spirochaete detection RPA primer and probe, the RPA primer is designed on the basis of lyme disease spirochaete recA gene, and primer sequences are as shown in Seq ID No: 1 and 2. The probe is designed on the basis of the RPA primer, and has a size of 46-52bp, 5 'end of the probe is marked with FAM, 3' end of the probe is modified by C3Spacer, and dSpacer or THF modification is performed at a position 30bp apart from the 5 'end of the probe. The present invention further provides a kit comprising the RPA primer and the probe. The present invention further provides a lyme disease spirochaete detection RPA method baed on the RPA primer and the probe. By combined use of RPA primer isothermal amplification technology and lateral flow chromatography test paper, lyme disease spirochaetes can be quickly and accurately detected from serum of suspicious patients. The specificity and sensitivity of the method are higher than that of conventional PCR, the method can be used for detecting lyme disease spirochaetes of different pathogenic genotypes, has important significance for lyme disease early diagnosis and treatment and other aspects of the lyme disease, can eliminates excessively high instrument cost, and is easy to promote and use in grassroots.

Mucosal administration of OspA and compositions therefor are disclosed and claimed. More particularly, oral administration of OspA and compositions therefor for eliciting an immunological response against Borrelia burgdorferi, such as a protective response preventive of Lyme disease are disclosed and claimed. Thus, oral Lyme disease vaccines or immunological compositions and methods of use are disclosed and claimed.

The related fast detection agent for syphilis spirochete antibody comprises a fast detection paper prepared by cellulose nitrate covered by pure syphilis spirochete monoclonal antibody and dried gold-mark monoclonal antibody. Wherein, with colloid gold immune chromatography technology and double antigen sandwich way, detecting syphilis spirochete and its fragment in humor, secretion and culture. This invention has more clinic meaning, high specificity, well sensitivity, and fit to wide spread.

Methods of treating, preventing and/or managing a spirochete and/or other obligate intracellular bacterial disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent.

The present invention relates, generally, to the production of one or more OspA proteins in plant cells. Heterologous DNA comprising genes encoding one or more desired OspA protein(s) are introduced into plant cells. The one or more OspA protein(s) can be recombinantly-produced in the plant cells, optionally purified from the plant cells, and used as an oral vaccine to prevent the transmission of Lyme disease, particularly by animal vectors. The recombinantly-produced OspA protein(s) can be provided in oral and parenteral formulations. The present invention also relates to oral administration of OspA protein(s) to vaccinate against Lyme disease. The OspA protein(s) may be provided in a dosage form that is suitable for oral administration as a vaccine to prevent an animal from developing Lyme disease after exposure to a source of Borrelia burgdorferi.

The invention relates to a loop-mediated isotheral amplification method (LAMP) for detecting Lyme disease pathogen in tick bodies, which is characterized by taking 16S rRNA gene as the target gene, using special software to design the LAMP for detecting the primers of the Lyme disease pathogen-Borrelia burgdorferi in the tick bodies, then selecting the primer of the specific fragment of the Lyme disease pathogen from the primers, extracting DNA after piercing the ticks to be detected, uniformly mixing the obtained DNA and the reaction buffer, the reaction mixture of the selected primer of the specific fragment and DNA polymerase to carry out amplification, adding loading buffer after activating the amplified product, then placing the mixture into agarose gel containing ethidium bromide to carry out electrophoresis detection and detecting whether the detected ticks carry the Lyme disease pathogen according to whether the specific band occurs after electrophoresis.